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0. Abstract  
Introduction: Carisoprodol, a frequently used muscle relaxant, can cause potentially fatal 
intoxications. Conversion to its active metabolite meprobamate is almost solely mediated by 
cytochrome P450 2C19 (CYP2C19), and mutations in this enzyme could have significant 
effects on serum concentrations. The objective of this study was to investigate the role of 
CYP2C19 genetics in mortalities due to carisoprodol intoxication. 
Methods: The frequencies of CYP2C19 variant alleles were compared between the study 
group (n 0 75) and two control groups, i.e. (1) deaths where carisoprodol was detected in the 
blood of the deceased, but intoxication was not the cause of death (control group A, n 0 38), 
and (2) a healthy population not using carisoprodol (control group B, n 0 185). In the study 
group and control A, the concentrations of carisoprodol and meprobamate were compared 
between the different genotype subgroups. 
Results: The variant allele frequencies of CYP2C19 did not differ significantly between the 
study group and control groups. Moreover, no statistically significant difference in the 
concentrations of carisoprodol and meprobamate between the different genotype subgroups 
was found. 
Conclusions: This study finds no evidence for an important association between CYP2C19 
genetics and mortality risk of carisoprodol. Other factors, such as co-administration with other 
drugs, likely play a more important role. 
3 
 
1. Introduction 
Carisoprodol is a centrally acting muscle relaxant used for acute back pain [1], but there are 
also reports of abuse [2-4] and deaths [5-7] attributed to the drug. We have previously 
published a report on 98 fatal carisoprodol intoxications and showed that the full blood 
carisoprodol concentrations were lower than previously published [8, 9], thus indicating that 
carisoprodol has a more narrow therapeutic index than assumed earlier [10].  
 
Carisoprodol has an unknown mechanism of action, but reveals effects like tachycardia and 
dizziness [11]. It is metabolised almost solely via the genetic polymorphic enzyme CYP2C19 
to the active metabolite meprobamate, which has barbiturate-like properties. The CYP2C19 
gene comprises different alleles, where the *1 (wild type) allele encodes normal activity, and 
the *2, 3 and 4 variant alleles codes for no activity (‘deficient’ variant alleles). The 
CYP2C19*17 variant allele has been attributed to increased enzyme activity but the 
phenotypic impact has been variable in different studies [12].  
 
In the case of carisoprodol, it is likely that carriers of deficient CYP2C19 variant alleles obtain 
higher concentrations of the parent drug, which may imply an increased risk of intoxications 
when considering carisoprodol’s narrow therapeutic index. On the other hand, it is a 
possibility that carriers of the CYP2C19*17 variant allele obtain higher concentrations of the 
toxic metabolite meprobamate. The aim of the present study was therefore to investigate if 
presence of CYP2C19 variant alleles is associated with increased risk of fatal intoxications 
with carisoprodol.  
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2. Materials and methods 
The Norwegian Institute of Public Health, Division of Forensic Medicine and Drug Abuse 
Research routinely analyses for drugs in blood samples from 90% of the forensic autopsies 
performed in Norway. The material in the present study constitutes all such cases in the 
period January 1
st
 2000 to December 31
st
 2003 in which carisoprodol and/or its metabolite 
meprobamate were detected. Meprobamate was rarely used as a drug as such in Norway, and 
when meprobamate was detected alone, the finding was considered to represent intake of 
carisoprodol. In the following, we therefore refer to the detection of carisoprodol when either 
carisoprodol or its metabolite was detected.  
 
After approval from the Norwegian Data Inspectorate, the official cause of death was 
recorded, and the cases were divided into those who died from intoxication with carisoprodol 
(study group) and a control group (control A) of those who died from other causes, but with 
carisoprodol detected in blood [10]. CYP2C19 genotyping was carried out in all cases where a 
post mortem blood sample was still available. The study was approved by the regional 
Committee for Medical and Health Research Ethics as well as the Norwegian Higher 
Prosecuting authority, which stand as the official owners of the forensic material.  
 
Carisoprodol and meprobamate were analysed in samples of post mortem full blood using a 
liquid chromatography-mass spectrometry method [10]. CYP2C19 genotyping was carried out 
using validated and certified Taqman-based real-time PCR assays developed for routine 
analysis at Centre for Psychopharmacology, Diakonhjemmet Hospital, Norway. CYP2C19 
genotyping included analysis of the *2, *3 and *17 variant alleles. Absence of these variant 
alleles was interpreted as presence of the wild type (*1) allele. 
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The CYP2C19 allele frequencies and genotype frequencies in the study group were compared 
with two control groups, i.e control A (described above) and previously published data from 
185 healthy Swedes who were not users of carisoprodol (control B) [13]. This is shown in 
table 1. Detailed genotype data from control B were kindly provided via e-mail by Eleni 
Aklillu, Department of laboratory medicine at Karolinska University Hospital, Stockholm, 
Sweden. Genotype and variant allele frequencies were compared using Fisher’s exact test. 
Differences in frequencies between the subgroups were calculated as odds ratios (OR) with 
95% confidence intervals. The blood concentrations of carisoprodol, meprobamate and the 
ratio meprobamate/carisoprodol were compared between the different genotype groups using 
Kruskal-Wallis non-parametric rank analysis of variance to establish an overall difference 
between the CYP2C19 genotype groups. Eventually, Dunn´s post test was applied for 
multiple comparisons. GraphPad Prism version 4 was used as software for statistical analyses. 
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3. Results 
The different groups and number of subjects are shown in table 1. In the study group, the 
cases were classified according to the importance of carisoprodol, using previously published 
criteria [10]. Three cases involved carisoprodol only, while 27 cases involved other drugs, but 
not in fatal concentrations. Carisoprodol was therefore considered the most important 
intoxicating drug. In the final 45 cases, additional drugs were present in fatal concentrations, 
and carisoprodol could therefore be less important as an intoxicating agent (table 1). 
  
The CYP2C19 allele frequencies for the *1, *2 and *17 alleles in the study group, control A 
and control B are shown in table 2. There were no detected *3 alleles in the study group or 
control A. This allele is also previously described to be very rare in the Caucasian population 
[13]. Variant allele frequencies of the *1, *2 or *17 alleles did not differ significantly between 
the study group and any of the control groups (table 2).  
 
The CYP2C19 genotype frequencies in the study group and control groups are shown in table 
3. Genotype frequencies did not differ significantly between the study group and any of the 
control groups (table 3), except from a lower frequency of the *1/*2 genotype in the study 
group compared to control A (OR 0.33, p=0.03).  
 
The allele frequencies and genotype frequencies were also compared excluding the cases from 
the study group where carisoprodol was less important as an intoxicating agent. When using 
only the study group cases in which carisoprodol was the only, or most important intoxicating 
agent (n=30), no difference in allele frequencies or genotype frequencies was seen compared 
to control A or control B. 
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There were no statistically significant differences in concentrations of carisoprodol or 
meprobamate (study group and control A together, n=113) between the different genotype 
groups (p>0.05 for trend for both carisoprodol and meprobamate). There was no statistically 
significant difference in the meprobamate/carisoprodol ratio between the different genotype 
groups (p>0.05 for trend). If concentrations of carisoprodol, meprobamate and the ratio 
meprobamate/carisoprodol were assessed within the study group and control A, respectively, 
there were no statistically significant difference in concentrations or ratio between the 
different genotype groups (p>0.05 for trend) (figure 1).  
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4. Discussion 
 
In this study, we found no significant differences in frequencies of CYP2C19 variant alleles 
among 75 subjects who died of intoxication with carisoprodol compared to i) those who died 
from other causes than intoxication, but with carisoprodol detected in blood, or ii) healthy 
individuals. This study therefore failed to find evidence for an important association between 
CYP2C19 genetics and the risk of fatal toxicity induced by carisoprodol. With regard to the 
single significant difference in genotype frequency, i.e. a lower proportion of CYP2C19*1/*2 
carriers in the study group compared to control A, we consider this to be a coincidence as the 
frequency of this genotype did not differ between the study group and healthy subjects.  
 
When interpreting studies yielding negative results, statistical power is an important issue to 
consider. Given the allele frequency of CYP2C19*1 in healthy controls (0.64 in control group 
B), post hoc calculations showed that the present study would have an 80% power to detect a 
significant difference if *1 allele frequency was below 0.45 or above 0.81 in the study group 
(n=75). For the *2 allele, the corresponding numbers were 0.04 and 0.32. Thus, it is 
reasonable to interpret that the sample size of the study was sufficient to detect clinically 
relevant differences in allele frequencies of the *1 and *2 alleles between study group and 
control B, except from decreased presence of the *2 allele in the study group.  
 
The relation between CYP2C19 genotype and deaths from carisoprodol has never been 
studied before. However, a small number of previous studies have failed to find a relation 
between CYP2C19 genotype and fatal intoxications, regardless of drug detected [14, 15]. This 
was strengthened by the present study. The limited impact of CYP genetics on risk of fatal 
drug-induced toxicity could have several explanations. Most important, a vast majority of the 
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intoxications in the present study involved multiple misuse agents, which are likely to 
potentiate each others toxic effects.  
 
We did not find concentration differences of carisoprodol and meprobamate between the 
different CYP2C19 genotype groups. This is in contrast to what have been observed in living 
subjects in former studies. For carisoprodol, a 30% longer terminal half life and a 40% higher 
area under the curve have previously been reported in *1/*2 subjects [11, 16]. However, a 
post mortem material is much less controlled with respect to dose ingested and presence of 
steady state level. Also, it is possible that post mortem redistribution may change blood 
concentrations after death, a phenomenon which is likely to be more pronounced for 
meprobamate than carisoprodol, considering their different volumes of distribution. Together, 
this could have masked the relatively moderate expected concentration differences between 
*1/*1 and *1/*2 subjects. The pharmacokinetic differences between homozygous wild type 
carriers and *2/*2 subjects have previously been reported to be more pronounced [11], but 
unfortunately we had too few subjects with the latter genotype to compare these subgroups.  
 
The strength of this study was the inclusion of a relatively large number of fatal toxicity cases 
and the fact that all subjects died from intoxication with carisoprodol, a known CYP2C19 
substrate. Moreover, another strength of the present study was the use of the official cause of 
death, which is set after all examinations are completed. The most important weakness of the 
present study was the involvement of other drugs than carisoprodol in most of the cases, a 
well known problem in forensic medicine [9]. When analysing the data only using the cases 
where carisoprodol was the only, or most important intoxicating drug (n=30), no difference to 
the control groups were seen, neither in allele frequencies nor genotype frequencies. Such 
reduction of the study group sample size would reduce the power and demand larger 
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differences in allele frequencies before it would yield statistically significant results. Also, the 
control group from the normal population was not users of carisoprodol. 
 
In conclusion, this study suggests that CYP2C19 genetics is not an important risk factor for 
carisoprodol-associated mortality. Other factors, such as dynamic interactions with other 
drugs, probably play a more important role in fatal intoxications.
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 Table 1. The different groups of subjects in the present study 
Group  Role of carisoprodol n 
Study group Deaths from 
intoxication 
Carisoprodol only 3 
Carisoprodol most 
important 
27 
Carisoprodol less 
important 
45 
Control A Deaths from other 
causes (e.g violent 
deaths) 
Carisoprodol 
detected 
38 
Control B Healthy individuals Not users of 
carisoprodol 
185 
 
Table 2. CYP2C19 allele frequencies and odds ratios (OR, 95% CI) in the study group (fatal 
intoxications) versus the respective control groups. Control A = deaths from other causes, 
control B = normal population.  
 Study group Control A OR (95% CI) Control B OR (95% CI) 
n 75 38  185  
*1 0.69 0.67 1.11 (0.61-2.00) 0.64 1.27 (0.84-1.90) 
*2 0.11 0.18 0.57 (0.26-1.22) 0.16 0.67 (0.39-1.20) 
*17 0.19 0.15 1.42 (0.66-3.02) 0.20 0.96 (0.59-1.55)  
 
 
Table 3. CYP2C19 allele frequencies and odds ratios (OR, 95% CI) in the study group (fatal 
intoxications) versus the respective control groups. Control A = deaths from other causes, 
control B = normal population. 
1
Significant value (p=0.03). 
 
 Study group Control A OR (95% CI) Control B  OR (95% CI) 
n 75 38  185  
*1/*1 35 (0.47) 15 (0.39) 1.34 (0.61-2.97) 76  (0.41) 1.26 (0.73-2.15)  
*1/*2 11 (0.15) 13 (0.34) 0.33 (0.13-0.84)
 1
 34  (0.18) 0.76 (0.36-1.60) 
*2/*2 1   (0.01) 0   (0.00) 1.55 (0.06-39.00) 7    (0.04) 0.34 (0.04-2.84) 
*2/*17 4   (0.05) 1   (0.03) 2.09 (0.23-19.34) 12  (0.07) 0.81 (0.25-2.61) 
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Figure 1. Log ratio meprobamate/carisoprodol in the different CYP2C19 genotype groups in 
study group (above) and control A (below). 
 
